News Zai Lab Limited

Stocks

ZLAB

US98887Q1040

Pharmaceuticals

Market Closed - Nasdaq 00:00:00 06/11/2026 +03			5-day change	1st Jan Change
22.60 ^USD	-0.88%		+1.07%	+28.12%

11-05	Zai Lab Q3 Loss Widens, Revenue Declines	MT
11-05	Zai Lab Limited, Q3 2026 Earnings Call, Nov 05, 2026

All News

Mentions Relevance

11-05	Zai Lab Q3 Loss Widens, Revenue Declines	MT
11-05	Zai Lab Limited, Q3 2026 Earnings Call, Nov 05, 2026
11-05	Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas	BU
11-05	Zai Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
11-05	Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Revenue $108.2M, vs. FactSet Est of $107.9M	MT
11-05	Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Revenue $108.2M, vs. FactSet Est of $107.9M	MT
11-05	Earnings Flash (ZLAB) Zai Lab Limited Reports Q3 Loss of $0.41 per ADS, vs. FactSet Est of $-0.58	MT
11-05	Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates	BU
10-26	Zai Lab's Lung Cancer Drug Achieves Promising Response Rate in Phase 1b Trial; Shares up 4%	MT
10-23	Zai Lab Limited - Special Call
10-23	Zai Lab Says Zoci Plus Atezolizumab Improves Response Rate in Phase 1 Lung Cancer Trial	MT
10-23	Zai Lab Limited Shares First Data From Global Phase 1b Clinical Trial Evaluating Zocilurtatug Pelitecan In Combination With Atezolizumab With And Without Carboplatin As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer	CI
10-23	Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer	BU
10-23	Zai Lab to Privately Place $250 Million in ADRs to Fund Drug Research	MT
10-23	Zai Lab to Raise $250 Million in Private Placement of ADSs	MT
10-23	Zai Lab Announces $250 Million Private Placement	BU
10-22	Zai Lab Limited announced that it expects to receive $249.9336 million in funding	CI
10-21	Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026	BU
10-14	Zai Lab Limited to Present Data from First Clinical Trial Evaluating ZL 1503, an Il-13/Il-31Ra Bispecific Antibody, for Atopic Diseases	CI
10-14	Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases	BU
09-29	Zai Lab Limited To Present First Global Data From Clinical Trial Evaluating Zocilurtatug Pelitecan As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer	CI
09-29	Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)	BU
08-26	Zai Lab's Net Loss Widens 14% in H1, Revenue Drops 6%	MT
08-17	Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis	BU
08-17	Zai Lab Limited and Argenx Announces Positive Topline Results From Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis	CI